1. Home
  2. HASI vs PTGX Comparison

HASI vs PTGX Comparison

Compare HASI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hannon Armstrong Sustainable Infrastructure Capital Inc.

HASI

Hannon Armstrong Sustainable Infrastructure Capital Inc.

HOLD

Current Price

$40.07

Market Cap

5.4B

Sector

Real Estate

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$94.19

Market Cap

6.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HASI
PTGX
Founded
1981
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
6.4B
IPO Year
2012
2016

Fundamental Metrics

Financial Performance
Metric
HASI
PTGX
Price
$40.07
$94.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
13
Target Price
$44.38
$108.23
AVG Volume (30 Days)
935.7K
478.7K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
4.20%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.05
Revenue
$400,502,000.00
N/A
Revenue This Year
$79.17
$874.25
Revenue Next Year
$207.88
N/A
P/E Ratio
N/A
$1,908.20
Revenue Growth
4.41
N/A
52 Week Low
$24.40
$49.86
52 Week High
$44.13
$107.84

Technical Indicators

Market Signals
Indicator
HASI
PTGX
Relative Strength Index (RSI) 45.42 39.72
Support Level $39.74 $90.58
Resistance Level $42.11 $98.27
Average True Range (ATR) 0.93 3.75
MACD -0.17 -0.90
Stochastic Oscillator 29.63 8.17

Price Performance

Historical Comparison
HASI
PTGX

About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.

HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition. The company's single reportable segment generates net investment and equity method investment income through investments in energy transition assets and infrastructure projects, as well as revenue through the gain on sale of assets and recurring asset management fees.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: